No black box warning on record for Valacyclovir Hydrochloride

As of the latest FDA labeling reviewed, Valacyclovir Hydrochloride (VALACYCLOVIR) does not carry a black box warning. Standard warnings and precautions still apply — see the full Valacyclovir Hydrochloride medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Has occurred in patients with advanced HIV-1 disease and in allogenic bone marrow transplant and renal transplant patients receiving 8 grams per day of valacyclovir tablets in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. ( 5.1 ) A

No black box warning on record for Valacyclovir Hydrochloride

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Has occurred in patients with advanced HIV-1 disease and in allogenic bone marrow transplant and renal transplant patients receiving 8 grams per day of valacyclovir tablets in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. ( 5.1 ) A

Valacyclovir Hydrochloride Black Box Warning

No black box warning on record for Valacyclovir Hydrochloride

Other warnings & precautions

Valacyclovir Hydrochloride Black Box Warning

No black box warning on record for Valacyclovir Hydrochloride

Other warnings & precautions